Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose 4.1% during mid-day trading on Wednesday . The company traded as high as $8.26 and last traded at $8.19, with a volume of 530,045 shares. The stock had previously closed at $7.87.

ACHN has been the subject of a number of research reports. Robert W. Baird reissued an “outperform” rating and set a $10.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, June 6th. JMP Securities raised Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 target price for the company in a research note on Thursday. Leerink Swann reissued a “hold” rating and set a $9.00 target price on shares of Achillion Pharmaceuticals in a research note on Wednesday, May 25th. Zacks Investment Research raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Tuesday, April 26th. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, May 5th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $10.43.

The company’s market capitalization is $1.22 billion. The company’s 50 day moving average is $8.78 and its 200-day moving average is $8.11.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.01. During the same period last year, the business earned ($0.17) earnings per share. On average, analysts forecast that Achillion Pharmaceuticals Inc. will post ($0.65) earnings per share for the current year.

Several institutional investors recently bought and sold shares of ACHN. Rhumbline Advisers raised its position in Achillion Pharmaceuticals by 14.0% in the fourth quarter. Rhumbline Advisers now owns 117,525 shares of the biopharmaceutical company’s stock worth $1,268,000 after buying an additional 14,425 shares in the last quarter. ProShare Advisors LLC raised its position in Achillion Pharmaceuticals by 10.1% in the fourth quarter. ProShare Advisors LLC now owns 126,923 shares of the biopharmaceutical company’s stock worth $1,370,000 after buying an additional 11,681 shares in the last quarter. Swiss National Bank raised its position in Achillion Pharmaceuticals by 6.8% in the fourth quarter. Swiss National Bank now owns 152,400 shares of the biopharmaceutical company’s stock worth $1,644,000 after buying an additional 9,700 shares in the last quarter. Morgan Stanley raised its position in Achillion Pharmaceuticals by 738.4% in the fourth quarter. Morgan Stanley now owns 233,221 shares of the biopharmaceutical company’s stock worth $2,517,000 after buying an additional 205,405 shares in the last quarter. Finally, Marshall Wace LLP raised its position in Achillion Pharmaceuticals by 36.8% in the fourth quarter. Marshall Wace LLP now owns 970,862 shares of the biopharmaceutical company’s stock worth $10,476,000 after buying an additional 261,007 shares in the last quarter.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.